idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Science Video Project
idw-Abo

idw-News App:

AppStore

Google Play Store



Instance:
Share on: 
11/26/2024 11:02

MHH team investigates the effectiveness of metformin for primary cancer prevention

Inka Burow Stabsstelle Kommunikation
Medizinische Hochschule Hannover

    A German Cancer Aid study offers people with Li-Fraumeni syndrome new preventive strategies: Researchers at Hannover Medical School (MHH) are investigating for the first time in a new efficacy study whether cancer-free survival can be extended in LFS sufferers with the daily intake of metformin.

    Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome (CPS) in which almost all sufferers are diagnosed with cancer at least once in their lives. Many are diagnosed as children or adolescents. In a new efficacy study, researchers at Hannover Medical School (MHH) are investigating for the first time whether cancer-free survival in LFS sufferers can be extended by taking metformin daily. Over a period of five to seven years, 300 patients will be included. The study is being funded with around 2.5 million euros from German Cancer Aid. Professor Dr Christian Kratz, Director of the Department of Paediatric Haematology and Oncology at the MHH, is leading the study, which is due to start in summer 2025.

    Participants can make an active contribution to personal cancer prevention

    Metformin is a drug that is mainly used to treat type 2 diabetes. Preclinical studies suggest that the drug may be able to reverse changes that favour cancer in LFS. ‘In our study, patients have the opportunity to actively participate in cancer prevention. The disease burden of LFS significantly reduces an individual's quality of life. So far, there has been a lack of strategies to enable LFS patients to actively participate and improve their quality of life. This is where we can now start,’ explains Dr Farina Silchmüller, assistant physician at the Department of Paediatric Haematology and Oncology and co-initiator of the study.

    Comprehensive cancer screening measures

    Intensified cancer screening measures have been the recommended standard worldwide since birth, as they have been shown to have a positive impact on overall survival. Professor Kratz and his team are going one step further by investigating cancer-free survival in LFS patients who participate in cancer screening plus daily metformin use. Patients who participate in the screening programme without additional metformin administration will serve as a comparison group. The participants in the study are randomly assigned to a group.

    Common types of cancer in LFS patients are breast cancer, soft tissue and bone sarcomas, brain tumours, leukaemias and adrenocortical carcinomas. ‘In the metformin group, the study participants take the drug daily under strict risk-minimising safety precautions.

    In addition, all participants receive comprehensive examinations for early cancer detection such as annual whole-body MRI, head MRI, an annual ultrasound of the abdomen and pelvis and skin cancer screening,’ explains Dr Silchmüller.

    Important basis for improved care

    This study is the first to analyse the effectiveness of LFS as a cancer prevention measure. In addition, information on the psychological stress of the participants will be collected. This data is particularly helpful for treatment practice and will enable a large number of subsequent clinical studies. ‘Our goal is of course to improve survival and increase quality of life,’ explains Dr Silchmüller.

    ‘The concept was developed as part of an international collaboration. A comparable study is already underway in England, and studies are currently being planned in the USA and Canada. Together with our partners in other countries, we are planning an international meta-analysis in order to achieve even more meaningful results,’ says Professor Kratz.

    The MHH's Centre for Clinical Studies (ZKS), the Institutes of Biometry, Clinical Pharmacology and Diagnostic and Interventional Radiology and the Department of Psychosomatics and Psychotherapy are also involved in the study.


    Contact for scientific information:

    For further information, please contact Professor Dr Christian Kratz, Kratz.Christian@mh-hannover.de, +495115326712.


    Images

    Does metformin help prevent cancer for LFS sufferers? Researchers Dr Farina Silchmüller and Professor Dr Christian Kratz from the MHH with a patient.
    Does metformin help prevent cancer for LFS sufferers? Researchers Dr Farina Silchmüller and Professo ...
    Karin Kaiser
    Karin Kaiser/MHH


    Criteria of this press release:
    Journalists, Scientists and scholars
    Medicine
    transregional, national
    Research projects
    English


     

    Does metformin help prevent cancer for LFS sufferers? Researchers Dr Farina Silchmüller and Professor Dr Christian Kratz from the MHH with a patient.


    For download

    x

    Help

    Search / advanced search of the idw archives
    Combination of search terms

    You can combine search terms with and, or and/or not, e.g. Philo not logy.

    Brackets

    You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).

    Phrases

    Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.

    Selection criteria

    You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).

    If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).